TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Investing.com

Anavex Life Sciences Crashes as EMA Setback Sparks Doubts on Lead Alzheimer Drug

Investing.com Logo Investing.com • •By Timothy Fries
Anavex Life Sciences Crashes as EMA Setback Sparks Doubts on Lead Alzheimer Drug

Anavex Life Sciences experienced a significant stock decline after receiving a negative trend vote from the European Medicines Agency regarding its Alzheimer's drug blarcamesine, causing shares to plummet approximately 50% in premarket trading.

Insights
QBTS.WS   negative

High-risk investment with slim chances of success in a competitive quantum computing landscape


AVXL   negative

Received a negative trend vote from EMA for its lead Alzheimer's drug, causing a 50% stock price drop, reducing market capitalization, and raising doubts about the drug's European approval prospects